Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
RFK Jr. Faces Scrutiny Over David Geier’s HHS Role and Vaccine Review Work 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
FDA Warns Novo Nordisk Over Misleading Ozempic Ad Claims 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
FDA Biologics Chief Vinay Prasad to Leave Agency in April Amid Policy Disputes 
Novo Nordisk Shares Tumble After CagriSema Misses Key Trial Endpoint 
Shares of women’s healthcare company Organon & Co (NYSE: OGN) climbed sharply in after-hours trading on Thursday following reports that India-based Sun Pharmaceutical Industries Ltd. (NSE: SUN) is preparing a $13 billion acquisition offer. The news sparked strong investor interest, pushing Organon stock up as much as 8% to above $9.20 per share.
The surge comes despite Organon’s relatively modest market capitalization of $2.2 billion at the close of regular trading, highlighting the significant premium implied by the reported deal. According to sources cited by The Economic Times, Sun Pharma is planning to submit a binding all-cash offer, with financing reportedly backed by major global banks including JPMorgan, MUFG, and Citi.
The potential acquisition signals Sun Pharma’s strategic push to expand its footprint in the fast-growing women’s healthcare segment. Organon, a spin-off from Merck, specializes in reproductive health, biosimilars, and established medicines, making it an attractive target for global pharmaceutical companies seeking diversification and innovation in healthcare portfolios.
Reports also indicate that Sun Pharma intends to fully integrate Organon into its existing operations rather than issuing shares to Organon investors. This move suggests a long-term commitment to leveraging Organon’s capabilities, particularly its U.S.-based manufacturing infrastructure, which is considered a valuable asset in the pharmaceutical industry.
The deal has reportedly drawn competition from Germany’s Gruenthal, underscoring the increasing demand for companies focused on women’s health solutions. As pharmaceutical giants race to strengthen their pipelines and global reach, acquisitions like this could reshape the competitive landscape.
Investors and analysts are closely watching developments, as confirmation of the deal could significantly impact both companies’ valuations and the broader healthcare sector. The potential buyout highlights the growing importance of women’s health in global pharma strategies, while reinforcing Organon’s position as a key player in this specialized market.
